Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zopiclone
Drug ID BADD_D02397
Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved
ATC Code N05CF01
DrugBank ID DB01198
KEGG ID D01372
MeSH ID C515050
PubChem ID 5735
TTD Drug ID D0ZB7K
NDC Product Code 66639-265; 64330-058; 63190-0030; 65372-1185
UNII 03A5ORL08Q
Synonyms zopiclone | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | Zop | Zopicalma | zopiclodura | Zopiclon AbZ | Zopiclon AL | Zopiclon AZU | Zopiclon beta | Zopiclon Stada | Zopiclon TAD | zopiclon von ct | Zopiclon-neuraxpharm | Zopiclon-TEVA | Zopitan | Zorclone | Imovane | Ximovan | Zimovane | Limovan | Nu-Zopiclone | Optidorm | ratio-Zopiclone | Zopiclon-ratiopharm | Rhovane | RP 27 267 | Siaten | Somnosan | Zileze | Zimoclone | Zopi-Puren | Zopicalm
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 43200-80-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnambulism17.15.02.004; 19.02.03.006--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Stress19.06.02.004--Not Available
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Therapeutic response unexpected08.06.01.001--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue coated07.14.02.011--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue movement disturbance17.02.05.049; 07.14.02.016--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene